Arbutus reported a smaller net loss in Q3 2025 due to significant cost reductions in R&D and G&A expenses. Revenue declined slightly year-over-year, and the company maintained a solid cash position of $93.7M to support ongoing HBV programs.

Arbutus Biopharma reported Q4 2024 revenue of $1.57 million and an EPS loss of -$0.07, outperforming expectations slightly. The company continued to manage its cash position effectively, with $122.62 million in cash, cash equivalents, and investments. Key developments included pipeline evaluations and corporate restructuring.

Arbutus Biopharma reported a net loss of $19.7 million for the third quarter of 2024, with total revenue of $1.3 million. The company's cash runway extends into the fourth quarter of 2026, and it is advancing the development of imdusiran and AB-101.

Arbutus Biopharma reported a net loss of $19.8 million for the second quarter of 2024. The company is prioritizing the Phase 2b clinical development of imdusiran and has reduced its workforce by 40%, extending its expected cash runway into the fourth quarter of 2026. As of June 30, 2024, the company's cash, cash equivalents, and investments totaled $148.5 million.

Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, with total revenue of $1.5 million. The company's cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2024, expected to fund operations through the second quarter of 2026.

Arbutus Biopharma reported its Q4 and year-end 2023 financial results, highlighting key clinical data expected in 2024 and a strong financial position with $132M in cash and investments.

Arbutus Biopharma reported a revenue of $4.7 million and a net loss of $20.1 million for the third quarter of 2023. The company is reducing its workforce by 24% and expects its cash runway to extend into the first quarter of 2026.

Arbutus Biopharma reported a total revenue of $4.7 million for the second quarter of 2023, compared to $14.2 million for the same period in 2022. The net loss for the quarter was $17.1 million, or $0.10 per share, compared to a net loss of $14.2 million, or $0.10 per share, for the same period in 2022. Cash, cash equivalents and investments in marketable securities totaled $163.5 million as of June 30, 2023.

Arbutus Biopharma Corporation reported a total revenue of $6.7 million for the first quarter of 2023, compared to $12.6 million for the same period in 2022. The net loss was $16.3 million, or $0.10 per share, compared to a net loss of $15.8 million, or $0.11 per share, for the same period in 2022. Cash, cash equivalents and investments in marketable securities were $178.5 million as of March 31, 2023.

Arbutus Biopharma Corporation reported its fourth quarter and year end 2022 financial results. The company highlighted progress in advancing its proprietary programs in chronic HBV and Coronavirus. They ended the year with $184.3 million in cash, cash equivalents and investments.

Arbutus Biopharma Corporation reported a total revenue of $6.0 million for the third quarter of 2022, compared to $3.3 million for the same period in 2021. The net loss attributable to common shares was $17.6 million, or a loss of $0.12 per basic and diluted common share, as compared to a net loss attributable to common shares of $24.2 million, or a loss of $0.24 per basic and diluted common share, for the three months ended September 30, 2021.

Arbutus Biopharma reported a revenue increase of $11.9 million compared to the same period in 2021, primarily due to revenue recognition from a license agreement with Qilu. The company's net loss attributable to common shares was $14.2 million, an improvement from the $22.7 million loss in the same quarter of the previous year. The company's cash runway is projected into the second quarter of 2024.

Arbutus Biopharma Corporation reported first quarter 2022 financial results, highlighting progress in chronic hepatitis B virus (cHBV) and pan-coronavirus programs, and a strong financial position with a projected cash runway into the second quarter of 2024. Revenues increased significantly due to a license agreement, while the net loss decreased compared to the same period last year.

Arbutus Biopharma Corporation reported its Q4 and year end 2021 financial results, highlighting the expansion of development efforts in Hepatitis B and coronavirus infections. The company anticipates reporting data from four clinical trials in chronically infected HBV patients in 2022 and expects to complete IND-enabling studies for two oral compounds to treat HBV in the second half of 2022.

Arbutus Biopharma Corporation reported a net loss attributable to common shares of $24.2 million for the third quarter of 2021. The company's cash, cash equivalents, and investments totaled $151.9 million as of September 30, 2021, which they believe is sufficient to fund operations into the second quarter of 2023.

Arbutus Biopharma Corporation reported a net loss attributable to common shares of $22.7 million ($0.23 basic and diluted loss per common share) for the three months ended June 30, 2021. The company had cash, cash equivalents and investments totaling $121.3 million as of June 30, 2021.

Arbutus Biopharma Corporation reported its first quarter 2021 financial results. The company had cash, cash equivalents and investments totaling $132.0 million as of March 31, 2021. Net loss attributable to common shares for the three months ended March 31, 2021 was $19.6 million ($0.21 basic and diluted loss per common share).

Arbutus Biopharma Corporation reported its fourth quarter and year-end 2020 financial results. The company's lead compound, AB-729, showed potential as a cornerstone drug in future HBV combination regimens. Several Phase 2 proof-of-concept combination clinical trials are expected to initiate this year. Arbutus expects a net cash burn between $70 to $75 million in 2021 and believes its cash runway extends through the third quarter of 2022.

Arbutus Biopharma reported its third quarter 2020 financial results. The company had cash, cash equivalents and investments totaling $118.3 million as of September 30, 2020. Net loss attributable to common shares for the three months ended September 30, 2020 was $21.8 million ($0.27 basic and diluted loss per common share).

Arbutus Biopharma Corporation reported its second quarter 2020 financial results. The company had cash, cash equivalents and investments totaling $84.0 million as of June 30, 2020. Net loss attributable to common shares for the three months ended June 30, 2020 was $17.1 million ($0.25 basic and diluted loss per common share).

Arbutus Biopharma reported a net loss attributable to common shares of $16.8 million, or $0.25 per share, for the first quarter of 2020. The company's cash, cash equivalents, and investments totaled $88.1 million as of March 31, 2020, which is expected to fund operations into mid-2021. Arbutus is advancing its clinical trials and preclinical research, including a new research initiative to identify novel antiviral therapies for COVID-19.

Arbutus Biopharma Corporation reported its fourth quarter and year end 2019 financial results. The company ended the year with $90.8 million in cash, cash equivalents and short-term investments. A net loss of $164.9 million was reported for the year ended December 31, 2019.